TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28993346
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment arm
Study: 27260839
Drug: Talactoferrin (TLf)
Normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talactoferrin (TLf) 150 mg/kg every 12 hours for 28 days
Study: 24929798
Drug: Moderate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate or intense supervised exercise training thrice-weekly for 12 weeks
Study: 12424329
Drug: Lycopene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplementation (30 mg of lycopene from tomato oleoresin extract)
Study: 10090434
Drug: 5-day grepafloxacin
Normalized name: GREPAFLOXACIN
DrugBank: Grepafloxacin (DB00365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day grepafloxacin 400 mg once daily
Study: 10090434
Drug: 10-day grepafloxacin
Normalized name: GREPAFLOXACIN
DrugBank: Grepafloxacin (DB00365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day grepafloxacin 400 mg once daily
Study: 85162
Drug: Domperidone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (60 mg daily) with bromocriptine (mean dose 148 mg daily)
Study: 85162
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with bromocriptine (average daily dose 92 mg)
Study: 26873098
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BTJ) 250 ml
Study: 26873098
Drug: Whole beetroot
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole beetroot (BF) 300 g
Study: 25531167
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of JIT training and real-time VisF
Study: 19673331
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SMI) 0.6 mL/kg in 250 mL physiological saline
Study: 19673331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 250 mL physiological saline
Study: 16983914
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SMI)
Study: 16840747
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered by intravenous infusion at Weeks 0, 2, and 6
Study: 11273875
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) 0.3 mg/kg
Study: 11273875
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (100 mg of Fe saccharate)
Study: 3057832
Drug: CSF-HU (P-100)
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF-HU (P-100) administered at 2 vials/day (8 X 10(6)U of P-100) by intravenous drip infusion for 7 days starting from the 5th day after chemotherapy initiation.
Study: 3057832
Drug: Placebo (inactive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive) administered in the same manner as P-100.
Study: 28034509
Drug: MAXCOG intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAXCOG intervention (four weekly sessions of individualized cognitive rehabilitation)
Study: 11766459
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin response (4th quartile)
Study: 9710042
Drug: Myoblast implantation
Normalized name: Bioblast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoblast implantation therapy (60 million myoblasts in one tibialis anterior muscle)
Study: 9710042
Drug: Cyclosporine immunosuppression
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine immunosuppression (5 to 10 mg/kg for 1 year)
Study: 12424547
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg caffeine
Study: 3414514
Drug: Nadolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (160 mg/day)
Study: 2744903
Drug: Diltiazem (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (240 mg/day)
Study: 3414514
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nadolol and diltiazem
Study: 22776824
Drug: Dapagliflozin 2.5
Normalized name: dapagliflozin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 2.5 mg
Study: 26208687
Drug: Maternal zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal zinc supplementation (20 mg/day elemental zinc)
Study: 23615868
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (GXR) 4 mg
Study: 23519656
Drug: Methylphenidate extended
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate extended release (MPH) 36 mg
Study: 21206549
Drug: Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Oxybate (SXB) 9 g nightly
Study: 21206549
Drug: Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Oxybate (SXB) 6 g and 9 g nightly
Study: 27778193
Drug: Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Oxybate (SXB) (all doses)
Study: 14556820
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for 20 weeks
Study: 7956390
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol (15 mg)
Study: 7956390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of furosemide (40 mg) and metaproterenol (15 mg)
Study: 3674548
Drug: Low‐ or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐ or high‐dose epimestrol administration schedule
Study: 24105358
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (Control)
Study: 18928378
Drug: Valacyclovir, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir, 500 mg twice daily
Study: 16642611
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus Chinese medicine
Study: 16642611
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus Chinese medicine
Study: 10801246
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (150 microg desogestrel and 30 microg ethinyl estradiol)
Study: 10801246
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no oral contraceptive)
Study: 1433426
Drug: 975 mg
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg aspirin 30 min after 10 g activated charcoal
Study: 1433426
Drug: 975 mg
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg aspirin 60 min after 10 g activated charcoal
Study: 1433426
Drug: 975 mg
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg aspirin alone
Study: 3812052
Drug: High-nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-nicotine cigarettes (0.9 mg)
Study: 3812052
Drug: Low-nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-nicotine cigarettes (0.002 mg)
Study: 26540397
Drug: IV haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV haloperidol 1 mg every 6 hours
Study: 24755126
Drug: Warfarin (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (1.25 mg/day, with possible increase to 1.75-2.25 mg/day based on INR)
Study: 17261397
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day)
Study: 17916662
Drug: BH(4) (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH(4) (400 mg twice daily)
Study: 16358138
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (twice a day)
Study: 8619011
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patches (17.5 mg)
Study: 1664253
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Fragmin) 2,500 XaI U 2 h before operation
Study: 1664253
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Fragmin) 5,000 XaI U 10 h before surgery
Study: 1664253
Drug: Unfragmented heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfragmented heparin (UH) 5,000 IU before operation
Study: 7032413
Drug: Tinidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (500 mg infusion over 30 minutes before surgery)
Study: 29131124
Drug: levofloxacin-containing bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: levofloxacin-containing bismuth quadruple therapy (RBAL)
Study: 29131124
Drug: standard bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard bismuth quadruple therapy (RBMT)
Study: 29131124
Drug: levofloxacin-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: levofloxacin-containing triple therapy (RAL)
Study: 21248398
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid with ketorolac (3 weekly injections of HA with ketorolac followed by 2 weekly injections of HA)
Study: 21248398
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid alone (5 weekly injections of HA)
Study: 19685727
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment applied to Baihui (GV 20), Danzhong (CV 17), Zhongwan (CV 12) for 14 sessions, once every other day.
Study: 17699988
Drug: Bupivacaine 1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.875 mg/kg alone (Group B)
Study: 17699988
Drug: Bupivacaine 1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.875 mg/kg with 2 microg/kg neostigmine (Group BN 2)
Study: 17699988
Drug: Bupivacaine 1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.875 mg/kg with 3 microg/kg neostigmine (Group BN 3)
Study: 17699988
Drug: Bupivacaine 1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.875 mg/kg with 4 microg/kg neostigmine (Group BN 4)
Study: 7973143
Drug: Intact whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact whole milk (360 mL)
Study: 7973143
Drug: 90% lactose-hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90% lactose-hydrolyzed milk (360 mL)
Study: 2537239
Drug: Topical tar
Normalized name: Doak 2% Topical Tar Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tar treatment
Study: 31852380
Drug: 100 or
Normalized name: Stalevo 100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 300 μg/kg of rVIIa-FP
Study: 30582447
Drug: Inhaled nebulized
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulized albuterol
Study: 25926678
Drug: Ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 5 mg twice a day + standard medical therapy (bisoprolol 1.25 mg once daily)
Study: 25926678
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (bisoprolol 2.5 to 3.75 mg once daily)
Study: 19235853
Drug: Intradermal influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal influenza vaccination with half the antigenic content
Study: 19235853
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular vaccination
Study: 11144401
Drug: Amoxicillin/clavulanate potassium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate potassium, cefprozil, azithromycin (Control)
Study: 9058627
Drug: Rectal enemas
Normalized name: Enema
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal enemas containing butyrate
Study: 9058627
Drug: Rectal enemas
Normalized name: Enema
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal enemas containing a mixture of short-chain fatty acids (SCFAs)
Study: 7940601
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin-C administration
Study: 3763291
Drug: MMR +
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR + V vaccine
Study: 30580974
Drug: Daily preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily preventive zinc tablets (7 mg/d)
Study: 30580974
Drug: High‐zinc, low‐iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐zinc, low‐iron micronutrient powder (10 mg/d zinc, 6 mg/d iron, and 13 other micronutrients)
Study: 30580974
Drug: Therapeutic zinc
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic zinc supplementation for diarrhea (20 mg/d for 10 days per episode)
Study: 30580974
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo powder
Study: 25787216
Drug: Ranibizumab combined
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab combined with photodynamic therapy (PDT)
Study: 25787216
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Ranibizumab monotherapy and combination therapy)
Study: 25787216
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (PDT)
Study: 20381283
Drug: Warfarin genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin genotyping
Study: 20381283
Drug: Warfarin genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin genotyping (per-protocol analysis)
Study: 20664903
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (ASA and clopidogrel)
Study: 18060244
Drug: Standardized fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized fixed dose antiplatelet therapy
Study: 12766123
Drug: Actovegin 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin 5% cream (Control)
Study: 10655920
Drug: Etomidate in
Normalized name: etomidate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate in propylene glycol formulation
Study: 10655920
Drug: Etomidate in
Normalized name: etomidate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate in lipid emulsion formulation
Study: 8877243
Drug: Nasal decongestant-antihistamine
Normalized name: Nasal Decongestant-Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal decongestant-antihistamine (nasal oxymetazolone and oral syrup containing brompheniramine and phenylpropanolamine)
Study: 8877243
Drug: Placebo (nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nasal saline and oral syrup)
Study: 30819162
Drug: STarT Back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STarT Back Tool (STarT-G) classification
Study: 29551346
Drug: Desensitizing-containing 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing-containing 10% carbamide peroxide gel (3% potassium nitrate and 0.2% sodium fluoride)
Study: 29551346
Drug: Desensitizing-free 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing-free 10% carbamide peroxide gel
Study: 26750677
Drug: McGrath (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: McGrath (MG) laryngoscope
Study: 24509697
Drug: Probiotic tablets
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic tablets containing L. reuteri strain (Prodentis)
Study: 24509697
Drug: No probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No probiotic tablet treatment (Control Group 2)
Study: 21051677
Drug: High-dose interferon-{alpha}
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-{alpha} treatment for 4 weeks
Study: 21051677
Drug: Low-dose interferon-{alpha}
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon-{alpha} treatment for 4 weeks
Study: 7573849
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 5 mg aerosol
Study: 2660632
Drug: Ketotifen syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen syrup
Study: 7428417
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of debrisoquin and mefruside
Study: 28011809
Drug: Low TT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low TT group receiving 430 mg of 70% pure TTs (300 mg TT)
Study: 28011809
Drug: High TT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TT group receiving 860 mg of 70% pure TTs (600 mg TT)
Study: 28011809
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving 860 mg olive oil
Study: 24961753
Drug: Evacetrapib 600
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 600 mg
Study: 21983371
Drug: Methylprednisolone infusion
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone infusion (n = 55)
Study: 19578220
Drug: Plapheron LB
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plapheron LB in dose of 0.028 mg/kg two times a day sublingually for ten days
Study: 19578220
Drug: Ordinary program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary program of intensive therapy
Study: 11314833
Drug: Intramuscular metaraminol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular metaraminol (0.1 mg x kg(‐1))
Study: 11314833
Drug: Intravenous boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous boluses (0.01 mg x kg(‐1))
Study: 11314833
Drug: Infusion (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion (0.05 mg x kg(‐1) x h(‐1))
Study: 9041052
Drug: Insulin‐like growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐like growth factor‐I (IGF‐I) administration, 40 micrograms/kg of body weight/day, for 1 week
Study: 9041052
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, then 0.250 IU/kg of body weight/week, for 24 months
Study: 7957464
Drug: Wide‐spectrum antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide‐spectrum antibiotic therapy with macrolide and mepartricin
Study: 28228162
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg fixed-dose LABA/LAMA combination
Study: 26237742
Drug: MenACWY-TT booster
Normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT booster dose
Study: 24192207
Drug: Raloxifene (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (not specified dosage or duration)
Study: 21068346
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL orange juice
Study: 21068346
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL control drink plus hesperidin (CDH)
Study: 21068346
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL control drink plus placebo (CDP)
Study: 14627972
Drug: Intermittent, hyperkalaemic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent, hyperkalaemic, diluted cold blood (15 degrees C), anterograde cardioplegia (CC)
Study: 2235671
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of heparin (3000 to 12,000 U) administered prior to hemodialysis
Study: 2235671
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose
Study: 28810
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (Bendrofluazide)
Study: 31335301
Drug: Ethinylestradiol/levonorgestrel (EE/LNG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol/levonorgestrel (EE/LNG) 30/150 μg co-administered with atazanavir/cobicistat (ATV/COBI) 300/150 mg
Study: 28072447
Drug: Eicosapentaenoic acid-enriched
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid-enriched diet (ProSure®), 600 kcal with 2.2 g eicosapentaenoic acid, for 7 days before and 21 days after surgery
Study: 26103654
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment + patient education
Study: 18004124
Drug: Lamotrigine (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (100-400 mg/d)
Study: 17453342
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment for 2 years
Study: 11472654
Drug: Immediate provisional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate provisional protocol for single-tooth implant replacement
Study: 31783004
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 3.6 mL of articaine and 1 mL of dexamethasone (4‐mg/mL solution) with 1 mL of saline solution